In the pharmacological treatment of schizophrenia, more and more authors suggesting the use of injectable antipsychotics long-term these patients, since it increases adherence to treatment, one of the risk factors for relapse that argues most often to explain the failure of the treatment of these patients.

In the present study, it is to observe the evolution of a group of such patients to assess efficacy and tolerability of treatment with Aripiprazole LAI.

Data from 17 patients treated at a mental health center in Navarra (Spain), diagnosed with schizophrenic disorder, followed over a year after beginning treatment with Aripiprazol LAI are collected.

The data collected are:

– date of treatment change (month and year);

– antipsychotic previous;

– reason for change;

– aripiprazole LAI dose;

– number of income before and after the start of Aripiprazole LAI (mirror);

– effects adverse pre and post start of treatment with Aripiprazole LAI: metabolic, endocrine, extrapyramidal;

– treatment antipsychotic concomitant pre and post start Aripiprazole LAI.

The results show a decrease in the number of income after the start with Aripiprazole LAI, with very good retention of treatment, and a low number of side effects, which were mild.

Treatment with Aripiprazole LAI is a good therapeutic alternative to the use of antipsychotic drugs by mouth, with good adherence, tolerability and efficacy.

The authors have not supplied their declaration of competing interest.